2008
DOI: 10.1136/gut.2007.137802
|View full text |Cite
|
Sign up to set email alerts
|

Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model

Abstract: In vitro studies show that the presence of both ligands on the same bispecific molecule is responsible for the superior activity of DTEGF13. Intratumoural administration showed that DTEGF13 was highly effective in checking aggressive tumour progression in mice. Lack of weight loss in these mice indicated that the drug was tolerated and a therapeutic index exists in an "on target" model in which DTEGF13 is cross-reactive with native mouse receptors.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
20
1

Year Published

2009
2009
2015
2015

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 23 publications
(22 citation statements)
references
References 40 publications
1
20
1
Order By: Relevance
“…A bispecific cytotoxin targeting receptors for epidermal growth factor and human IL-13 is shown to be effective in animal model of pancreatic cancer (13). IL-13 plays a central role in inflammation and immune responses and binds to two receptor subunits, IL-13Rα1 and IL-13Rα2 (14).…”
Section: Introductionmentioning
confidence: 99%
“…A bispecific cytotoxin targeting receptors for epidermal growth factor and human IL-13 is shown to be effective in animal model of pancreatic cancer (13). IL-13 plays a central role in inflammation and immune responses and binds to two receptor subunits, IL-13Rα1 and IL-13Rα2 (14).…”
Section: Introductionmentioning
confidence: 99%
“…18,19 Recombinant cytotoxic fusion proteins carrying the enzymatically active portion of the DT and receptor-binding domains of IL-2 or of IL-3 have been successfully used in the treatment of T-cell lymphoma and acute myeloid leukemia in human beings. 20,21 An immunotoxin construct consisting of the vehicle, epidermal growth factor (EGF) and the toxin, DT, has been used for PC immunotoxin therapy in vitro, and in animal models, [22][23][24] as EGF receptor (EGFR) is known to be over-expressed in this tumor type. 25 However, EGFR expression by tissue, other than pancreatic tumor tissue, may cause nonspecific toxicity with side effects, such as fever, pain, hypoalbuminemia, increased transaminase levels and vascular leakage.…”
Section: Introductionmentioning
confidence: 99%
“…Targeted toxins provide a unique opportunity for tumor therapy, offering an advantage of unique specificity and limiting potential toxicity to normal tissues. A bispecific cytotoxin that consists of Diptheria toxin, epidermal growth factor, and human IL-13 is shown to be effective in inducing tumor cell killing in vitro and in vivo against the MiaPaCa-2 cell line (20). Furthermore, IL-13PE38QQR and IL-4PE38QQR have also shown cytotoxic effects in some of the pancreatic cell lines in vitro (21).…”
mentioning
confidence: 99%